WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Bristol-Myers Squibb

Bristol-Myers SquibbBristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

www.bms.com.

Bristol-Myers Squibb RSS Channel

Filters
List of articles in category Bristol-Myers Squibb
Title Published Date
Bristol-Myers Squibb and Ambrx Announce Collaboration 22 September 2011
Bristol-Myers Squibb and Ono Enter into Strategic Agreement 21 September 2011
Bristol-Myers Squibb Completes Acquisition of Amira Pharmaceuticals 09 September 2011
Bristol-Myers Squibb Delivers Excellent Second Quarter 05 August 2011
Bristol-Myers Squibb to Acquire Amira Pharmaceuticals 22 July 2011
FDA Advisory Committee Makes Recommendation on Investigational Compound Dapagliflozin 21 July 2011
Bristol-Myers Squibb and Innate Pharma Announce Breakthrough Global License Agreement 07 July 2011
Bristol-Myers Squibb to Expand Access to Reyataz® in sub-Saharan Africa and India 29 June 2011
Bristol-Myers Squibb Foundation Awards $1.5 Million in Grants 27 June 2011
Bristol-Myers Squibb and Roche Enter into a Clinical Collaboration Agreement 03 June 2011
Bristol-Myers Squibb Delivers Excellent First Quarter with YERVOY™ (ipilimumab) Approval 29 April 2011
Phase III Study of Investigational Compound Ipilimumab Achieves Primary Endpoint 22 March 2011
Bristol-Myers Squibb Delivers Solid Fourth Quarter Results 27 January 2011
Pediatric Exclusivity For PLAVIX® 25 January 2011
People to Actively Manage Their Type 2 Diabetes 11 January 2011
KOMBIGLYZE™ XR Now Available in U.S. Pharmacies 09 January 2011
Bristol-Myers Squibb and Oncolys BioPharma Enter Global Licensing Agreement 21 December 2010
Encouraging Phase 2 Interim Data for Elotuzumab in Relapsed Multiple Myeloma 07 December 2010
Bristol-Myers Squibb and Alvin Ailey American Dance Theater Announce First-of-Its-Kind Collaboration 01 December 2010
APPRAISE-2 Study with Investigational Compound Apixaban Discontinued 21 November 2010
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
  • End

Business & Industry

  • GSK completes acquisition of Sierra Oncology
  • Pfizer and BioNTech announce new agreement with U.S. government to provide additional doses of COVID-19 vaccine
  • Bayer opens new Research & Innovation Center in Boston-Cambridge demonstrating its commitment to precision oncology
  • New Novartis extension phase data show nearly 80% of RMS patients treated with Kesimpta® (ofatumumab) had no evidence of disease activity (NEDA-3)
  • Pfizer and BioNTech announce Omicron-adapted COVID-19 vaccine candidates demonstrate high immune response against Omicron

Research & Development

  • Researchers discover new leukemia-killing compounds
  • Oral antiviral drug effective against respiratory syncytial virus (RSV) identified by researchers
  • Biomarkers found that could be drug targets against a deadly form of brain cancer
  • COVID-19 rebound after taking Paxlovid likely due to insufficient drug exposure
  • Novel drug combo activates natural killer cell immunity to destroy cancer cells
  • Broadly neutralizing antibodies could provide immunity against SARS-CoV-2 variants
  • A new technology offers treatment for HIV infection through a single injection

Conferences & Events

  • New approach to treatment of deadly kidney cancer
  • SAE Media Group proudly presents the 2nd Annual Aseptic Processing Conference
  • Pharma join together to achieve new standards in digital and patient innovation for clinical transformation
  • SMi's 22nd Annual Pain Therapeutics Conference
  • SMi Group Introduces the 4th Annual Injectable Drug Delivery Conference 2022
  • SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference
  • SMi's 3rd Annual AI in Drug Discovery Conference

Regulatory Affairs

  • FDA approves first systemic treatment for alopecia areata
  • FDA urges drug manufacturers to develop risk management plans to promote a dtronger, resilient drug supply chain
  • FDA limits use of Janssen COVID-19 vaccine to certain individuals
  • EMA establishes Cancer Medicines Forum with academia to optimise cancer treatments in clinical practice
  • FDA approves first generic of Symbicort to treat asthma and COPD
  1. You are here:  
  2. Home
  3. Bristol-Myers Squibb
  4. Bristol-Myers Squibb reports first quarter financial results

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2022. All Rights Reserved.